Grifols (GRFS) Change in Cash (2010 - 2016)
Grifols (GRFS) posted Change in Cash of -$5.9 million for Q4 2016, up 99.09% quarter-over-quarter from -$644.6 million in Q3 2016, and up 95.67% year-on-year from -$3.0 million in Q1 2016.
Grifols (GRFS) Change in Cash (2010 - 2016) Analysis & Trends
Grifols (GRFS) has reported Change in Cash for 6 consecutive years, with -$5.9 million the latest figure, recorded in Q4 2016.
- Change in Cash for Q4 2016 came in at -$5.9 million, up 95.67% year-over-year; the trailing twelve-month figure through Dec 2016 was -$901.1 million (down 1520.11% YoY), and the FY2025 annual result was -$180.4 million, down 137.44% from the prior year.
- Change in Cash was -$5.9 million for Q4 2016 at Grifols, up from -$644.6 million in the prior quarter.
- Over five years, Change in Cash peaked at $631.9 million in Q2 2015 and troughed at -$644.6 million in Q3 2016.
- Average Change in Cash over 4 years is -$29.8 million, with a median of -$5.9 million recorded in 2016.
- Year-over-year, Change in Cash surged 39081.59% in 2013 and sank 462.04% in 2016.
- Over 4 years, Change in Cash stood at $94.3 million in 2012, then fell by 4.33% to $90.2 million in 2013, then sank by 250.57% to -$135.9 million in 2015, then surged by 95.67% to -$5.9 million in 2016.
- Per Business Quant data, the three most recent Change in Cash figures were -$5.9 million in Q4 2016, -$644.6 million in Q3 2016, and -$135.9 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -1.99 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 1.98 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.16 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 5.70 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -5.89 Mn |
| Sep 30, 2016 | -644.62 Mn |
| Dec 31, 2015 | -135.86 Mn |
| Sep 30, 2015 | -114.69 Mn |
| Jun 30, 2015 | 631.90 Mn |
| Mar 31, 2015 | -317.90 Mn |
| Dec 31, 2014 | -260.66 Mn |
| Sep 30, 2014 | 277.27 Mn |
| Jun 30, 2014 | -33.13 Mn |
| Mar 31, 2014 | 33.14 Mn |
| Dec 31, 2013 | 300.12 Mn |
| Sep 30, 2013 | 12.08 Mn |
| Jun 30, 2013 | -81.62 Mn |
| Mar 31, 2013 | 90.23 Mn |
| Dec 31, 2012 | 94.32 Mn |
| Sep 30, 2012 | 107.50 Mn |
| Jun 30, 2012 | -33.56 Mn |
| Mar 31, 2012 | 230,290.61 |
| Dec 31, 2011 | 239.85 Mn |
| Sep 30, 2011 | -109.46 Mn |